Patent law's reproducibility paradox

Duke Law Journal

Volumn 66, Issue 4, 2017, Pages 845-911

  Sherkow, Jacob S ^a  

^a NEW YORK LAW SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CONJUGATED ESTROGEN; DRUG COMBINATION; MEDROXYPROGESTERONE ACETATE; PROTEIN C; RECOMBINANT PROTEIN; TICLOPIDINE;

ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; DRUG DEVELOPMENT; DRUG RESEARCH; HUMAN; INTERPERSONAL COMMUNICATION; LEGISLATION AND JURISPRUDENCE; METHODOLOGY; PATENT; REPRODUCIBILITY; STATISTICS AND NUMERICAL DATA; UNITED STATES;

BEVACIZUMAB; CLINICAL TRIALS AS TOPIC; DISCLOSURE; DRUG COMBINATIONS; DRUG DISCOVERY; ESTROGENS, CONJUGATED (USP); HUMANS; MEDROXYPROGESTERONE ACETATE; PATENTS AS TOPIC; PHARMACEUTICAL RESEARCH; PROTEIN C; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; TICLOPIDINE; UNITED STATES;

EID: 85003770887     PISSN: 00127086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Francis S. Collins & Lawrence A. Tabak, NIH Plans to Enhance Reproducibility, 505 Nature 612, 612 (2014).
2. Leonard P. Freedman, Iain M. Cockburn & Timothy S. Simcoe, The Economics of Reproducibility in Preclinical Research, PLoS Biology, June 9, 2015, at 3.
3. Regina Nuzzo, Statistical Errors, 506 Nature 150, 150-52 (2014) (describing one instance of p-hacking).
4. Megan L. Head et al., The Extent and Consequences of P-Hacking in Science, PLoS Biology, Mar. 13 2015.
5. John P.A. Ioannidis, Stealth Research: Is Biomedical Innovation Happening Outside the Peer-Reviewed Literature?, 313 J. Am. Med. Ass'N 663, 663 (2015).
6. Victoria Stodden, Trust Your Science? Open Your Data and Code, 2011 AmStat News 21, 21.
7. Yale Law Sch. Roundtable on Data and Code Sharing, supra note 17, at 8.
8. John M. Conley, Robert Cook-Deegan & Gabriel Lázaro-Muñoz, Myriad After Myriad: The Proprietary Data Dilemma, 15 N.C. J.L. & TECH. 597, 613-16 (2014).
9. Dan L. Burk, Patents as Data Aggregators in Personalized Medicine, 21 B.U. J. SCI. TECH. L. 233, 239-240 (2015).
10. Jacob S. Sherkow & Christopher Scott, Myriad Stands Alone, 32 NATURE BIOTECHNOLOGY 620, 620 (2014) (discussing Myriad's patents as forming its secret database).
11. Brenda M. Simon & Ted M. Sichelman, Data-Generating Patents, 111 Nw. U. L. REV. (forthcoming 2017), http://ssrn.com/abstract=2753547 [https://perma.cc/A3X8-PRY5].
12. Monya Baker, Irreproducible Biology Research Costs Put at $28 Billion Per Year, Nature: News, (June 9, 2015), http://www.nature.com/news/irreproducible-biology-research-costs-put-at-28-billion-per-year-1.17711 [https://perma.cc/K4XR-969C.
13. Monya Baker, Blame It on the Antibodies, 521 Nature 274, 274 (2015) [hereinafter Baker, Antibodies].
14. Jason Rantanen, Peripheral Disclosure, 74 U. PITT. L. REV. 1, 6 (2012).
15. Alan Devlin, The Misunderstood Function of Disclosure in Patent Law, 23 HARV. J.L. & TECH. 401, 417-18 (2010). Delvin notes:
16. Jeffrey A. Lefstin, The Formal Structure of Patent Law and the Limits of Enablement, 23 BERKELEY TECH. L.J. 1141, 1164 n.78 (2008).
17. Dan L. Burk & Mark A. Lemley, Biotechnology's Uncertainty Principle, 54 CASE W. RES. L. REV. 691, 709 (2004).
18. Michael Risch, A Surprisingly Useful Requirement, 19 GEO. MASON L. REV. 57, 102 (2011).